This indicates that KL-VSHET+ status interaction with pathological aspects of AD are more profound among APOE ε4-carriers, such as Aβ and Tau accumulation during the pre-clinical phase of the disease [47, 48]. The gene discussed is MAPT; the disease is Alzheimer disease.